000843730 001__ 843730
000843730 005__ 20230217124532.0
000843730 0247_ $$2doi$$a10.1007/s00415-018-8761-7
000843730 0247_ $$2ISSN$$a0012-1037
000843730 0247_ $$2ISSN$$a0340-5354
000843730 0247_ $$2ISSN$$a0939-1517
000843730 0247_ $$2ISSN$$a1432-1459
000843730 0247_ $$2ISSN$$a1619-800X
000843730 0247_ $$2pmid$$apmid:29392459
000843730 0247_ $$2WOS$$aWOS:000428928200004
000843730 0247_ $$2Handle$$a2128/21355
000843730 0247_ $$2altmetric$$aaltmetric:32601461
000843730 037__ $$aFZJ-2018-01282
000843730 082__ $$a610
000843730 1001_ $$0P:(DE-HGF)0$$aEggers, Carsten$$b0$$eCorresponding author
000843730 245__ $$aPatient-centered integrated healthcare improves quality of life in Parkinson’s disease patients: a randomized controlled trial
000843730 260__ $$aBerlin$$bSpringer85301$$c2018
000843730 264_1 $$2Crossref$$3online$$bSpringer Science and Business Media LLC$$c2018-02-01
000843730 264_1 $$2Crossref$$3print$$bSpringer Science and Business Media LLC$$c2018-04-01
000843730 264_1 $$2Crossref$$3print$$bSpringer Science and Business Media LLC$$c2018-04-01
000843730 3367_ $$2DRIVER$$aarticle
000843730 3367_ $$2DataCite$$aOutput Types/Journal article
000843730 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524560729_25916
000843730 3367_ $$2BibTeX$$aARTICLE
000843730 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000843730 3367_ $$00$$2EndNote$$aJournal Article
000843730 520__ $$aIntroductionImproving quality of life (QoL) is a key issue when dealing with Parkinson’s disease (PD). Integrative care shows potential to achieve improvements in QoL. Here, we analyzed whether a community-based, open-label, integrated approach improves QoL in PD patients.MethodsPD patients were screened for eligibility and evaluated by a university-based PD specialist, a PD nurse, and a general neurologist at a local practice. Patients were randomly assigned to a control group (CG), receiving standard German neurological treatment including a baseline assessment and follow-up visit at 6 months, or an interventional group (IG) who received an individually tailored therapy plan and additional home visits. Patients and investigators were not blinded for either intervention. Primary outcome analysis compared the differential change of PDQ-39 from baseline to 6-month follow-up between CG and IG. Between-group changes in mood, motor/non-motor functioning, and cognition were secondary outcomes.Results300 patients were included and randomized equally to IG and CG. 132 IG and 125 CG patients had a valid PDQ-39 at follow-up and qualified for the modified ITT analysis. PDQ-39 improved more in IG compared to CG [2.2 points (95% CI − 4.4 to 0.1); p = 0.044]. Likewise, change scores between IG and CG favored IG for UPDRS III (p < 0.001, mean change 3.3, 95% CI − 4.9 to − 1.7) and PD-NMS (p < 0.001, mean change 11.3, 95% CI − 17.1 to − 5.5).ConclusionsData show that an integrated approach, compared to regular PD care, improves QoL as well as motor and nonmotor PD symptoms over 6 months. Future studies need to address the cost–benefit ratio and whether positive effects can be maintained beyond intervention.
000843730 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000843730 542__ $$2Crossref$$i2018-02-01$$uhttp://www.springer.com/tdm
000843730 588__ $$aDataset connected to CrossRef
000843730 7001_ $$0P:(DE-HGF)0$$aDano, R.$$b1
000843730 7001_ $$0P:(DE-HGF)0$$aSchill, J.$$b2
000843730 7001_ $$0P:(DE-Juel1)131720$$aFink, G. R.$$b3$$ufzj
000843730 7001_ $$0P:(DE-HGF)0$$aHellmich, M.$$b4
000843730 7001_ $$0P:(DE-HGF)0$$aTimmermann, L.$$b5
000843730 77318 $$2Crossref$$3journal-article$$a10.1007/s00415-018-8761-7$$bSpringer Science and Business Media LLC$$d2018-02-01$$n4$$p764-773$$tJournal of Neurology$$v265$$x0340-5354$$y2018
000843730 773__ $$0PERI:(DE-600)1421299-7$$a10.1007/s00415-018-8761-7$$n4$$p764-773$$tJournal of neurology$$v265$$x0340-5354$$y2018
000843730 8564_ $$uhttps://juser.fz-juelich.de/record/843730/files/10.1007_s00415-018-8761-7.pdf$$yRestricted
000843730 8564_ $$uhttps://juser.fz-juelich.de/record/843730/files/10.1007_s00415-018-8761-7.gif?subformat=icon$$xicon$$yRestricted
000843730 8564_ $$uhttps://juser.fz-juelich.de/record/843730/files/10.1007_s00415-018-8761-7.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000843730 8564_ $$uhttps://juser.fz-juelich.de/record/843730/files/10.1007_s00415-018-8761-7.jpg?subformat=icon-180$$xicon-180$$yRestricted
000843730 8564_ $$uhttps://juser.fz-juelich.de/record/843730/files/10.1007_s00415-018-8761-7.jpg?subformat=icon-640$$xicon-640$$yRestricted
000843730 8564_ $$uhttps://juser.fz-juelich.de/record/843730/files/10.1007_s00415-018-8761-7.pdf?subformat=pdfa$$xpdfa$$yRestricted
000843730 8564_ $$uhttps://juser.fz-juelich.de/record/843730/files/Eggers_2018epub_Post%20print_Journal%20of%20Neurology_Patient-centered%20integrated%20healthcare%20improves%20quality%20of%20life%20in%20Parkinson%27s%20disease%20patients.pdf$$yPublished on 2018-02-01. Available in OpenAccess from 2019-02-01.
000843730 8564_ $$uhttps://juser.fz-juelich.de/record/843730/files/Eggers_2018epub_Post%20print_Journal%20of%20Neurology_Patient-centered%20integrated%20healthcare%20improves%20quality%20of%20life%20in%20Parkinson%27s%20disease%20patients.pdf?subformat=pdfa$$xpdfa$$yPublished on 2018-02-01. Available in OpenAccess from 2019-02-01.
000843730 909CO $$ooai:juser.fz-juelich.de:843730$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000843730 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b3$$kFZJ
000843730 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000843730 9141_ $$y2018
000843730 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000843730 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000843730 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000843730 915__ $$0StatID:(DE-HGF)0530$$2StatID$$aEmbargoed OpenAccess
000843730 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROL : 2015
000843730 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000843730 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000843730 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000843730 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000843730 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000843730 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000843730 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000843730 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000843730 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000843730 920__ $$lyes
000843730 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000843730 980__ $$ajournal
000843730 980__ $$aVDB
000843730 980__ $$aUNRESTRICTED
000843730 980__ $$aI:(DE-Juel1)INM-3-20090406
000843730 9801_ $$aFullTexts
000843730 999C5 $$1P Barone$$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.22643$$p1641 -$$tMov Disord$$uBarone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Dotto PD (2009) The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649$$v24$$y2009
000843730 999C5 $$1D Berg$$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.25844$$p454 -$$tMov Disord$$uBerg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, Goetz CG, Halliday GM, Hardy J, Lang AE, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Disord 29:454–462$$v29$$y2014
000843730 999C5 $$1NJ Diederich$$2Crossref$$9-- missing cx lookup --$$a10.1212/01.wnl.0000324635.49971.3d$$p677 -$$tNeurology$$uDiederich NJ, Goetz CG (2008) The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies. Neurology 71:677–684$$v71$$y2008
000843730 999C5 $$1HC Diener$$2Crossref$$9-- missing cx lookup --$$a10.1055/b-002-37755$$uDiener HC, Weimar C (2012) Leitlinien für Diagnostik und Therapie in der Neurologie. Thieme, Leipzig$$y2012
000843730 999C5 $$1R Gray$$2Crossref$$9-- missing cx lookup --$$a10.1016/S0140-6736(14)60683-8$$p1196 -$$tLancet$$uGroup PDMC, Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE (2014) Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 384:1196–1205$$v384$$y2014
000843730 999C5 $$1RA Hauser$$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.23638$$p813 -$$tMov Disord$$uParkinson Study Group, Hauser RA, Auinger P (2011) Determination of minimal clinically important change in early and advanced Parkinson’s disease. Mov Disord 26:813–818$$v26$$y2011
000843730 999C5 $$1C Jenkinson$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.parkreldis.2015.09.008$$p1312 -$$tParkinsonism Relat Disord$$uJenkinson C, Clarke C, Gray R, Hewitson P, Ives N, Morley D, Rick C, Wheatley K, Williams A (2015) Comparing results from long and short form versions of the Parkinson’s disease questionnaire in a longitudinal study. Parkinsonism Relat Disord 21:1312–1316$$v21$$y2015
000843730 999C5 $$1P Martinez-Martin$$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.23834$$p2371 -$$tMov Disord$$uMartinez-Martin P, Jeukens-Visser M, Lyons KE, Rodriguez-Blazquez C, Selai C, Siderowf A, Welsh M, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG, Schrag A (2011) Health-related quality-of-life scales in Parkinson’s disease: critique and recommendations. Mov Disord 26:2371–2380$$v26$$y2011
000843730 999C5 $$1P Martinez-Martin$$2Crossref$$9-- missing cx lookup --$$a10.1586/erp.11.106$$p221 -$$tExpert Rev Pharmacoecon Outcomes Res$$uMartinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ (2012) Quality of life and burden in caregivers for patients with Parkinson’s disease: concepts, assessment and related factors. Expert Rev Pharmacoecon Outcomes Res 12:221–230$$v12$$y2012
000843730 999C5 $$1V Peto$$2Crossref$$9-- missing cx lookup --$$a10.1093/ageing/30.4.299$$p299 -$$tAge Ageing$$uPeto V, Jenkinson C, Fitzpatrick R (2001) Determining minimally important differences for the PDQ-39 Parkinson’s disease questionnaire. Age Ageing 30:299–302$$v30$$y2001
000843730 999C5 $$1V Peto$$2Crossref$$9-- missing cx lookup --$$a10.1007/BF02260863$$p241 -$$tQual Life Res$$uPeto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995) The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res 4:241–248$$v4$$y1995
000843730 999C5 $$1KM Prakash$$2Crossref$$9-- missing cx lookup --$$a10.1111/ene.12950$$p854 -$$tEur J Neurol$$uPrakash KM, Nadkarni NV, Lye WK, Yong MH, Tan EK (2016) The impact of non-motor symptoms on the quality of life of Parkinson’s disease patients: a longitudinal study. Eur J Neurol 23:854–860$$v23$$y2016
000843730 999C5 $$1K Rajiah$$2Crossref$$9-- missing cx lookup --$$a10.1159/000479031$$p131 -$$tNeuroepidemiology$$uRajiah K, Maharajan MK, Yeen SJ, Lew S (2017) Quality of life and caregivers’ burden of Parkinson’s disease. Neuroepidemiology 48:131–137$$v48$$y2017
000843730 999C5 $$1G Reinoso$$2Crossref$$9-- missing cx lookup --$$a10.1111/ene.12476$$p457 -$$tEur J Neurol$$uReinoso G, Allen JC Jr, Au WL, Seah SH, Tay KY, Tan LC (2015) Clinical evolution of Parkinson’s disease and prognostic factors affecting motor progression: 9-year follow-up study. Eur J Neurol 22:457–463$$v22$$y2015
000843730 999C5 $$1JY Shin$$2Crossref$$9-- missing cx lookup --$$a10.1177/1054773816634912$$p142 -$$tClin Nurs Res$$uShin JY, Habermann B (2017) Nursing research in Parkinson’s disease from 2006 to 2015: a systematic review. Clin Nurs Res 24:142–156$$v24$$y2017
000843730 999C5 $$1CL Tomlinson$$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.23429$$p2649 -$$tMov Disord$$uTomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653$$v25$$y2010
000843730 999C5 $$1M Eijk van der$$2Crossref$$9-- missing cx lookup --$$a10.3233/JPD-150673$$p937 -$$tJ Parkinsons Dis$$uvan der Eijk M, Bloem BR, Nijhuis FA, Koetsenruijter J, Vrijhoef HJ, Munneke M, Wensing M, Faber MJ (2015) Multidisciplinary collaboration in professional networks for PD. A mixed-method analysis. J Parkinsons Dis 5:937–945$$v5$$y2015
000843730 999C5 $$1MA Marck van der$$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.25194$$p605 -$$tMov Disord$$uvan der Marck MA, Bloem BR, Borm GF, Overeem S, Munneke M, Guttman M (2013) Effectiveness of multidisciplinary care for Parkinson’s disease: a randomized, controlled trial. Mov Disord 28:605–611$$v28$$y2013
000843730 999C5 $$1MA Marck van der$$2Crossref$$9-- missing cx lookup --$$a10.1016/S1474-4422(13)70196-0$$p947 -$$tLancet Neurol$$uvan der Marck MA, Munneke M, Mulleners W, Hoogerwaard EM, Borm GF, Overeem S, Bloem BR, Group Is (2013) Integrated multidisciplinary care in Parkinson’s disease: a non-randomised, controlled trial (IMPACT). Lancet Neurol 12:947–956$$v12$$y2013
000843730 999C5 $$1S Campenhausen von$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.euroneuro.2010.08.002$$p180 -$$tEur Neuropsychopharmacol$$uvon Campenhausen S, Winter Y, Rodrigues e Silva A, Sampaio C, Ruzicka E, Barone P, Poewe W, Guekht A, Mateus C, Pfeiffer KP, Berger K, Skoupa J, Botzel K, Geiger-Gritsch S, Siebert U, Balzer-Geldsetzer M, Oertel WH, Dodel R, Reese JP (2011) Costs of illness and care in Parkinson’s disease: an evaluation in six countries. Eur Neuropsychopharmacol 21:180–191$$v21$$y2011
000843730 999C5 $$1DT Wade$$2Crossref$$9-- missing cx lookup --$$a10.1136/jnnp.74.2.158$$p158 -$$tJ Neurol Neurosurg Psychiatry$$uWade DT, Gage H, Owen C, Trend P, Grossmith C, Kaye J (2003) Multidisciplinary rehabilitation for people with Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 74:158–162$$v74$$y2003
000843730 999C5 $$1A Williams$$2Crossref$$9-- missing cx lookup --$$a10.1016/S1474-4422(10)70093-4$$p581 -$$tLancet Neurol$$uWilliams A, Gill S, Varma T, Jenkinson C, Quinn N, Mitchell R, Scott R, Ives N, Rick C, Daniels J, Patel S, Wheatley K, Group PSC (2010) Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 9:581–591$$v9$$y2010
000843730 999C5 $$1K Kieburtz$$2Crossref$$9-- missing cx lookup --$$a10.1001/jama.2015.120$$p584 -$$tJAMA$$uWriting Group for the NETiPDI, Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB Jr, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Perez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM (2015) Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA 313:584–593$$v313$$y2015